What question did this study set out to answer?

To identify reliable cell-surface biomarkers that distinguish tumor antigen-specific CD8 tumor-infiltrating lymphocytes across primary and metastatic human solid cancers.

July 9, 2018Nature CommunicationsOpen Access

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

View Full Paper

Ask AI

Bookmark

Authors

TDThomas DuhenCancer Institute (WIA)RDRebekka DuhenOregon Health & Science University RMRyan MontlerAGCO (Netherlands)

Discussion

Member takes

Implication

Translational study reveals that CD103 and CD39 co-expression marks tumor-reactive CD8 T cells across human solid cancers, highlighting potential targets for personalized adoptive immunotherapies.

Key Points

To identify reliable cell-surface biomarkers that distinguish tumor antigen-specific CD8 tumor-infiltrating lymphocytes across primary and metastatic human solid cancers.
Profiled CD8 tumor-infiltrating lymphocytes (TILs) isolated from primary and metastatic lesions across six distinct human solid malignancies.
Assessed tissue-resident memory phenotypes, T-cell receptor (TCR) repertoires, and MHC class I-dependent cytotoxicity against autologous tumor cells.
Analyzed clinical cohorts to evaluate the association between CD103+CD39+ CD8 TIL abundance and overall survival in head and neck cancer.
CD103+CD39+ CD8 TILs were enriched for tumor-reactive cells across six solid malignancies, exhibiting an exhausted tissue-resident memory phenotype and tumor-expanded TCR clones.
CD103+CD39+ CD8 TILs efficiently killed autologous cancer cells via an MHC class I-dependent mechanism.
Increased frequencies of CD103+CD39+ CD8 TILs were significantly associated with superior overall survival in patients with head and neck cancer.

Cite This Study

Duhen et al. (2018) studied this question.

synapsesocial.com/papers/69dd47b37808b00a4799c0ac https://doi.org/10.1038/s41467-018-05072-0

View Full Paper

Ask AI

Bookmark

Implication

Translational study reveals that CD103 and CD39 co-expression marks tumor-reactive CD8 T cells across human solid cancers, highlighting potential targets for personalized adoptive immunotherapies.

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

Discussion

Member takes

Implication

Key Points

Cite This Study

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider